Porphyria

D. Montgomery Bissell; Karl E. Anderson; Herbert L. Bonkovsky

doi:10.1056/NEJMra1608634

Porphyria

D. Montgomery Bissell, Karl E. Anderson, Herbert L. Bonkovsky

Preventive Medicine & Community Health

Research output: Contribution to journal › Review article › peer-review

125 Scopus citations

Original language	English (US)
Pages (from-to)	862-872
Number of pages	11
Journal	New England Journal of Medicine
Volume	377
Issue number	9
DOIs	https://doi.org/10.1056/NEJMra1608634
State	Published - Aug 31 2017

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1056/NEJMra1608634

Cite this

@article{f3f5eb7ddd4c4b7fa3004de7d3ee4825,

title = "Porphyria",

author = "Bissell, {D. Montgomery} and Anderson, {Karl E.} and Bonkovsky, {Herbert L.}",

note = "Funding Information: Dr. Bissell reports receiving fees for participating in clinical trials from Clinuvel Pharmaceuticals and Alnylam Pharmaceuticals and receiving consulting fees from Recordati Rare Diseases and Mitsubishi Tanabe Pharma; Dr. Anderson, receiving grant support from Clinuvel Pharmaceuticals, Alnylam Pharmaceuticals, and Recordati Rare Diseases; and Dr. Bonkovsky, receiving grant support and consulting fees from Clinuvel Pharmaceuticals, Alnylam Pharmaceuticals, Recordati Rare Diseases, and Mitsubishi Tanabe Pharma. No other potential conflict of interest relevant to this article was reported.",

year = "2017",

month = aug,

day = "31",

doi = "10.1056/NEJMra1608634",

language = "English (US)",

volume = "377",

pages = "862--872",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "9",

}

TY - JOUR

T1 - Porphyria

AU - Bissell, D. Montgomery

AU - Anderson, Karl E.

AU - Bonkovsky, Herbert L.

N1 - Funding Information: Dr. Bissell reports receiving fees for participating in clinical trials from Clinuvel Pharmaceuticals and Alnylam Pharmaceuticals and receiving consulting fees from Recordati Rare Diseases and Mitsubishi Tanabe Pharma; Dr. Anderson, receiving grant support from Clinuvel Pharmaceuticals, Alnylam Pharmaceuticals, and Recordati Rare Diseases; and Dr. Bonkovsky, receiving grant support and consulting fees from Clinuvel Pharmaceuticals, Alnylam Pharmaceuticals, Recordati Rare Diseases, and Mitsubishi Tanabe Pharma. No other potential conflict of interest relevant to this article was reported.

PY - 2017/8/31

Y1 - 2017/8/31

UR - http://www.scopus.com/inward/record.url?scp=85028569502&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028569502&partnerID=8YFLogxK

U2 - 10.1056/NEJMra1608634

DO - 10.1056/NEJMra1608634

M3 - Review article

C2 - 28854095

AN - SCOPUS:85028569502

VL - 377

SP - 862

EP - 872

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 9

ER -

Porphyria

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this